NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · Real-Time Price · USD
0.783
+0.019 (2.43%)
At close: Sep 6, 2024, 4:00 PM
0.789
+0.006 (0.77%)
After-hours: Sep 6, 2024, 4:25 PM EDT
Company Description
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.
Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors.
The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
NKGen Biotech, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Paul Y. Song |
Contact Details
Address: 3001 Daimler Street Santa Ana, California 92705 United States | |
| Phone | 949-396-6830 |
| Website | nkgenbiotech.com |
Stock Details
| Ticker Symbol | NKGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001845459 |
| ISIN Number | US65488A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul Y. Song M.D. | Chief Executive Officer and Chairman |
| Dr. Yong Man Kim Ph.D. | Chief Scientific Officer |
| Sangwoo Park | Founder and Executive Director |
| James A. Graf | Interim Chief Financial Officer |
| Yoonmi Kang | SVice President of Technical Ops and Development |
| Irene Chang | SVice President, Human Resources and Corporate Culture |
| Denise A. Chua CLS, MBA, MT (ASCP) | SVice President of Corporate Affairs |
| Ryan Park C.F.A. | Executive Vice President of Financial Planning and Analysis and Corporate Strategy |
| Pierre Gagnon | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 30, 2024 | 8-K | Current Report |
| Aug 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 22, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 14, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 9, 2024 | 8-K | Current Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jul 29, 2024 | 8-K | Current Report |
| Jul 23, 2024 | ARS | Filing |
| Jul 22, 2024 | DEF 14A | Other definitive proxy statements |